title: Opioid inhibition of formalin-induced changes in plasma extravasation and local blood flow in rats.
abstract: Hindpaw injection of dilute formalin produces brief (Phase 1) and persistent (Phase 2) nociceptive responses in the rat. We recently showed that systemically-administered remifentanil during Phase 1 interacted with peripheral opioid receptors to delay the onset and termination of Phase 2 (Taylor et al., 1997b). To test the hypothesis that opioid inhibition of proinflammatory events during Phase 1 contributed to this delay, we evaluated the effects of remifentanil on the time course of formalin-induced inflammation. We found that formalin increased paw thickness (edema), plasma extravasation and local blood flow within minutes of its injection, i.e. during Phase 1. Each of these responses was blocked during remifentanil administration (30 microg/kg i.v. bolus, followed 90 s later with a 15 microg/kg/min infusion for 13.5 min), indicating that opioids inhibit Phase 1 inflammation. Opioid blockade of the blood flow response could be reversed with a peripherally-acting opioid antagonist, naloxone methiodide, indicating that remifentanil acted upon peripheral opioid receptors. Although the administration of remifentanil during Phase 1 did not reduce the magnitude of inflammatory responses during Phase 2, it did delay the onset and termination of edema during Phase 2. As this corresponds to the effects of remifentanil on nociceptive responses during Phase 2, we suggest that opioid analgesics act upon peripheral sites to inhibit inflammation during Phase 1, leading to a delay in the temporal profile of inflammatory (and likely nociceptive) responses during Phase 2.
authors.affiliation: W.M. Keck Foundation Center for Integrative Neuroscience and Departments of Anatomy and Physiology, University of California San Francisco, San Francisco, CA 94143, USA. taylorb@umkc.edu
authors.forename: B K
authors.initials: BK
authors.lastname: Taylor
authors.forename: M A
authors.initials: MA
authors.lastname: Peterson
authors.forename: R E
authors.initials: RE
authors.lastname: Roderick
authors.forename: J
authors.initials: J
authors.lastname: Tate
authors.forename: P G
authors.initials: PG
authors.lastname: Green
authors.forename: J O
authors.initials: JO
authors.lastname: Levine
authors.forename: A I
authors.initials: AI
authors.lastname: Basbaum
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D005557:Formaldehyde / Q000494:pharmacology*; D006614:Hindlimb / Q000098:blood supply* / Q000000981:diagnostic imaging; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology; D017078:Laser-Doppler Flowmetry; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D010949:Plasma / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D000077208:Remifentanil; D012881:Skin Temperature / Q000187:drug effects; D014463:Ultrasonography
chemical_list: D000701:Analgesics, Opioid; D010880:Piperidines; D005557:Formaldehyde; D000077208:Remifentanil